Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and/or metformin to modulate hormonal therapy response in hormone receptor-positive HER2-negative metastatic breast cancer after first-line hormonal therapy
2011-000155-16Phase 2Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Lapatinib arm, Metformin arm and Lapatinib + metformin arm (3 arms). Primary endpoint: Progression-free at 3 months. Started Mar 2012; status: terminated.
02
Drugs
lapatinibmetformin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-000155-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000155-16.